Internationally recognized hematologist John P. Chute, MD, has been selected to direct the Division of Hematology and Cellular Therapy in the Department of Medicine at Cedars-Sinai Cancer. The physician-scientist also will serve as director of the Center for Myelodysplastic Diseases Research and associate director of the Board of Governors Regenerative Medicine Institute in the Department of Biomedical Sciences.
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy.
MD Anderson and Allogene today announced a strategic five-year collaboration for preclinical and clinical investigation of allogeneic CAR T cell therapies.
Patients who develop cytomegalovirus infections after allogeneic stem cell transplantation may be able to develop an immunity against the virus, strengthen their immune system and reduce reliance on strong antiviral medications, a team from Roswell Park reports in the journal Biology of Blood and Marrow Transplantation.
A new report, published in Nature Reviews Drug Discovery, reveals that the cellular immunotherapy landscape continues to expand, with 472 more cellular therapies in development now than one year ago
The David and Etta Jonas Center for Cellular Therapy is being established at the University of Chicago Medicine to accelerate research in hard-to-treat cancers.
MD Anderson and Takeda today announced an exclusive license agreement and research agreement to develop CAR NK-cell therapies for the the treatment of B-cell malignancies.